La dagaallanka kansarka beerka oo leh Bioocus GPC3 CAR-T Therapy

Taariikhda Bukaanka

Pawan, oo ah shaqsi u heellan Hindiya, ayaa lagu ogaaday inuu qabo cudur beerka ah oo daba-dheeraaday oo ay ku adkaatay kansarka beerka ee multifocal (HCC) bishii Agoosto 2024. Isagoo 67 jir ah markii la ogaaday cudurka (isagoo 68 jir ah inta lagu jiro daaweynta), wuxuu la kulmay cudur daran oo leh nabarro badan oo beerka ah, calaamado buro oo kor u kacay sida AFP iyo PIVKA-II, dhiig-yaraan, cilladaha ensaymka beerka, iyo metastases lafaha dambe. In kasta oo uu maray transarterial radioembolization (TARE), transarterial chemoembolization (TACE), immunotherapy (Atezolizumab + Bevacizumab, Tremelimumab + Durvalumab), iyo daaweyn la beegsaday (Lenvatinib, Cabozantinib, Regorafenib), cudurkiisu wuu sii socday. Baaritaanka hidde-sidaha ayaa muujiyay isbeddello ku yimid TP53, KRAS, CDKN2A, CTNNB1, iyo ARID1A, oo leh muujinta PD-L1 oo hooseysa iyo tabanaanshaha HRD, taasoo muujinaysa jawaab celin xaddidan oo ku aaddan xannibaadaha qaarkood. Iyadoo raadineysa xalal horumarsan, Pawan waxaa loo gudbiyay Isbitaalka Kansarka ee Tianjin iyada oo loo marayo Bioocus si loogu sameeyo daaweynta GPC3 CAR-T ee otomaatiga ah iyadoo la adeegsanayo lambarka daaweynta P1544.

Safarka Daaweynta

Daawaynta CAR-T ee Pawan waxay ku bilaabatay leukapheresis Agoosto 11, 2025, waxaana ku xigay soo saarista iyo faleebada Sebtembar 2, 2025. Wuxuu helay qiyaas ah 4.73 × 10^8 unugyada CAR-T, isagoo bartilmaameedsanaya GPC3, oo ah calaamad aad u badan oo lagu muujiyey HCC. Xaaladda ka hor faleebada waxaa ka mid ahaa fludarabine iyo cyclophosphamide si loo xoojiyo faleebada. Kadib faleebada, dhiiggiisa durugsan ayaa lala socday fidinta CAR-T maalmaha 4 (D4), 7 (D7), 10 (D10), iyo 12 (D12).

• D4 (Sebtembar 6, 2025):Unugyada CAR-T ee 5.15% unugyada CD3+ T (qiimaha buuxa: 9.27 × 10^6/L), taasoo muujinaysa xaraashka bilowga ah.
• D7 (Sebtembar 9, 2025):Ugu sarreysay 3.97% (6.12 × 10^7/L), taasoo muujinaysa koror firfircoon.
• D10 (Sebtembar 12, 2025):04% (9.07 × 10^6/L).
• D12 (Sebtembar 14, 2025):Xasilooni 2.82% (2.26 × 10^7/L), iyadoo wadarta unugyada T ay tahay 5.4 × 10^9/L, CD3+ ay tahay 14.87%, unugyada T ee sunta ah ee CD8+ oo kor u kacay 77.88%, iyo qaybaha hoose ee CAR-T oo dheellitiran (tusaale ahaan, 2.46% CD8+CARGPC3+/CD8+).

Intii lagu jiray isbitaalka laga bilaabo Agoosto 11 ilaa Sebtembar 15, 2025, Pawan wuxuu la kulmay waxyeellooyin fudud, oo ay ku jiraan qandho heer hoose ah (ilaa 38.5°C), daal, iyo kor u kaca ensaymka beerka ee ku-meel-gaarka ah, si taageero leh ayaa loo maareeyay iyada oo aan lahayn cudurka sii deynta cytokine ee daran (CRS heerka 1) ama sunta neerfaha. Calaamadaha muhiimka ah ayaa ahaa kuwo deggan, daryeelka taageeradana waxaa ka mid ahaa ka-hortagga caabuqyada, nafaqada, iyo la socodka dhibaatooyinka sida ascites.

Natiijooyinka Heerka Sare ah

Ballaarinta CAR-T, inkastoo ay yar tahay, waxay muujisay adkeysi iyo firfircooni ka hortagga burooyinka, iyadoo la xiriirta calaamadaha burooyinka oo deggan oo aan lahayn horumar degdeg ah oo ku saabsan sawirka dabagalka. Kiiska Pawan wuxuu la jaan qaadayaa guusha Bioocus ee GPC3 CAR-T ee HCC, halkaas oo xitaa adkeysiga heerka hoose uu horseedi karo jawaabo waara oo ku yimaada bukaanada aan awoodin inay bogsadaan. Waxaa laga saaray xaalad deggan Sebtembar 15, 2025, iyadoo lagu taliyay in la socdo joogto ah, oo ay ku jiraan calaamadaha burooyinka, shaqada beerka, iyo baaritaannada PET-CT. Habka daaweyntan ee bartilmaameedka ah wuxuu yareeyay sunta nidaamsan iyadoo wax laga qabanayo deegaanka beerka ee burooyinka.